DiaMedica Therapeutics (DMAC) Short Interest Ratio & Short Volume $5.71 +0.04 (+0.71%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DiaMedica Therapeutics Short Interest DataDiaMedica Therapeutics (DMAC) has a short interest of 222,800 shares. This marks a 14.49% increase in short interest from the previous month. The short interest ratio (days to cover) is 2.4, indicating that it would take 2.4 days of the average trading volume of 80,418 shares to cover all short positions.Current Short Interest222,800 sharesPrevious Short Interest194,600 sharesChange Vs. Previous Month+14.49%Dollar Volume Sold Short$1.21 millionShort Interest Ratio2.4 Days to CoverLast Record DateDecember 31, 2024Outstanding Shares42,760,000 sharesPercentage of Shares Shorted0.52%Today's Trading Volume249,075 sharesAverage Trading Volume80,418 sharesToday's Volume Vs. Average310% Short Selling DiaMedica Therapeutics? Sign up to receive the latest short interest report for DiaMedica Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartDMAC Short Interest Over TimeDMAC Days to Cover Over TimeDMAC Percentage of Float Shorted Over Time DiaMedica Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/31/2024222,800 shares $1.21 million +14.5%N/A2.4 $5.43 12/15/2024194,600 shares $1.05 million +28.5%N/A2.2 $5.38 11/30/2024151,500 shares $857,490.00 -12.2%N/A1.8 $5.66 11/15/2024172,500 shares $691,725.00 -1.8%N/A2.4 $4.01 10/31/2024175,600 shares $767,372.00 -4.2%N/A3.6 $4.37 10/15/2024183,300 shares $815,685.00 +20.4%N/A3.5 $4.45 9/30/2024152,300 shares $638,137.00 +10.0%N/A2.8 $4.19 9/15/2024138,400 shares $622,800.00 -0.4%N/A1.9 $4.50 8/31/2024139,000 shares $546,270.00 -2.1%N/A2.1 $3.93 8/15/2024142,000 shares $498,420.00 -1.5%N/A2.3 $3.51 Get the Latest News and Ratings for DMAC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/2024144,200 shares $472,976.00 -17.0%N/A2.4 $3.28 7/15/2024173,700 shares $621,846.00 +10.8%N/A3 $3.58 6/30/2024156,800 shares $462,560.00 +22.1%N/A2.7 $2.95 6/15/2024128,400 shares $308,160.00 -1.9%N/A3.5 $2.40 5/31/2024130,900 shares $379,610.00 +1.8%N/A3.5 $2.90 5/15/2024128,600 shares $387,086.00 -29.3%N/A3.3 $3.01 4/30/2024182,000 shares $469,560.00 +3.8%N/A4.3 $2.58 4/15/2024175,400 shares $419,206.00 -13.3%N/A4.4 $2.39 3/31/2024202,200 shares $560,094.00 -4.9%N/A4.8 $2.77 3/15/2024212,600 shares $644,178.00 +8.3%N/A5 $3.03 2/29/2024196,300 shares $588,900.00 +3.7%N/A4.7 $3.00 2/15/2024189,300 shares $567,900.00 -3.3%N/A4.4 $3.00 1/31/2024195,700 shares $551,874.00 -3.1%N/A4 $2.82 1/15/2024202,000 shares $603,980.00 +7.0%N/A4 $2.99 12/31/2023188,800 shares $536,192.00 -2.2%N/A3.8 $2.84 12/15/2023193,100 shares $531,025.00 +5.4%N/A3.7 $2.75 11/30/2023183,300 shares $447,252.00 -24.9%N/A3.1 $2.44 11/15/2023244,200 shares $598,290.00 0.0%N/A4 $2.45 10/31/2023244,300 shares $532,574.00 +11.5%N/A4 $2.18 10/15/2023219,100 shares $449,155.00 -1.1%N/A2.9 $2.05 9/30/2023221,500 shares $571,470.00 +0.7%N/A2.3 $2.58 9/15/2023219,900 shares $712,476.00 -0.8%N/A1.8 $3.24 8/31/2023221,700 shares $654,015.00 -9.4%N/A1.5 $2.95 8/15/2023244,600 shares $725,239.00 -10.6%N/A1.5 $2.97 7/31/2023273,500 shares $924,430.00 -65.7%N/A1.6 $3.38 7/15/2023796,100 shares $3.01 million +11.6%4.5%5.4 $3.78 6/30/2023713,600 shares $3.08 million +910.8%4.0%5.4 $4.32 6/15/202370,600 shares $224,508.00 +7.1%0.4%0.7 $3.18 5/31/202365,900 shares $179,907.00 -21.2%0.4%1.1 $2.73 5/15/202383,600 shares $166,196.80 -9.0%0.5%1.9 $1.99Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. 4/30/202391,900 shares $149,797.00 -5.7%0.5%3.4 $1.63 4/15/202397,400 shares $155,840.00 +6.5%0.6%3.4 $1.60 3/31/202391,500 shares $139,995.00 +55.6%0.5%2.9 $1.53 3/15/202358,800 shares $104,664.00 +44.8%0.4%1.5 $1.78 2/28/202340,600 shares $70,238.00 -1.7%0.3%0.7 $1.73 2/15/202341,300 shares $62,363.00 +22.6%0.3%0.7 $1.51 1/31/202333,700 shares $45,495.00 -57.8%0.2%0.5 $1.35 1/15/202379,800 shares $130,872.00 -6.5%0.5%1.2 $1.64 12/30/202285,300 shares $134,782.53 +113.8%0.5%1.3 $1.58 12/15/202239,900 shares $60,249.00 -7.0%0.2%0.6 $1.51 11/30/202242,900 shares $51,051.00 +24.4%0.2%0.7 $1.19 11/15/202234,500 shares $39,330.00 -35.0%0.2%0.6 $1.14 10/31/202253,100 shares $62,658.00 -47.5%0.3%0.9 $1.18 10/15/2022101,200 shares $153,824.00 +245.4%0.6%1.9 $1.52 9/30/202229,300 shares $36,332.00 -61.7%0.2%0.4 $1.24 9/15/202276,500 shares $110,925.00 +153.3%0.4%0.5 $1.45 8/31/202230,200 shares $53,454.00 -43.6%0.2%0.2 $1.77 8/15/202253,500 shares $96,835.00 -0.2%0.3%0.4 $1.81 7/31/202253,600 shares $88,440.00 +10.7%0.3%0.4 $1.65 7/15/202248,400 shares $61,952.00 -8.2%0.3%0.4 $1.28 6/30/202252,700 shares $106,454.00 +5.0%0.3%0.4 $2.02 6/15/202250,200 shares $110,440.00 -1.6%0.3%1.1 $2.20 5/31/202251,000 shares $123,930.00 -50.3%N/A1.2 $2.43 5/15/2022102,700 shares $250,588.00 +85.4%N/A2.3 $2.44 4/30/202255,400 shares $128,528.00 +62.5%N/A1.2 $2.32 4/15/202234,100 shares $79,112.00 +5.9%N/A0.6 $2.32 3/31/202232,200 shares $80,500.00 -45.8%N/A0.5 $2.50 3/15/202259,400 shares $136,620.00 -26.0%N/A0.7 $2.30 2/28/202280,300 shares $211,189.00 -23.5%N/A0.7 $2.63 2/15/2022104,900 shares $325,190.00 +21.6%N/A0.9 $3.10 1/31/202286,300 shares $223,517.00 +14.9%0.5%0.6 $2.59 1/15/202275,100 shares $253,838.00 +22.1%0.4%0.4 $3.38 12/31/202161,500 shares $229,395.00 -22.5%0.3%0.4 $3.73 12/15/202179,300 shares $307,684.00 +55.8%0.4%0.4 $3.88 11/30/202150,900 shares $190,366.00 -26.9%0.3%0.3 $3.74 11/15/202169,600 shares $280,488.00 -21.5%0.4%0.3 $4.03 10/29/202188,700 shares $350,365.00 -7.9%0.6%0.4 $3.95 10/15/202196,300 shares $394,830.00 +62.4%0.6%0.5 $4.10 9/30/202159,300 shares $237,793.00 +9.6%N/A0.3 $4.01 9/15/202154,100 shares $209,367.00 +29.7%0.3%0.2 $3.87 8/31/202141,700 shares $179,310.00 +85.3%0.2%0.1 $4.30 8/13/202122,500 shares $69,750.00 -59.4%0.1%0.1 $3.10 7/30/202155,400 shares $191,130.00 -23.9%0.3%0.2 $3.45 7/15/202172,800 shares $264,992.00 -47.5%0.4%0.3 $3.64 6/30/2021138,700 shares $617,215.00 -26.9%0.8%0.6 $4.45 6/15/2021189,800 shares $1.64 million +27.7%1.1%1.9 $8.63 5/28/2021148,600 shares $1.10 million -6.8%0.9%1.6 $7.41 5/14/2021159,400 shares $1.03 million -2.8%N/A1.5 $6.47 4/30/2021164,000 shares $1.56 million -12.3%N/A1.4 $9.50 4/15/2021187,000 shares $1.78 million +8.4%N/A1.5 $9.54Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. 3/31/2021172,500 shares $1.58 million +10.0%N/A1.2 $9.18 3/15/2021156,800 shares $1.53 million +34.5%N/A0.8 $9.74 2/26/2021116,600 shares $1.08 million +40.5%N/A0.6 $9.25 2/12/202183,000 shares $728,740.00 -10.9%N/A0.3 $8.78 1/29/202193,100 shares $722,456.00 +17.0%N/A0.4 $7.76 1/15/202179,600 shares $780,876.00 -19.7%N/A0.4 $9.81 12/31/202099,100 shares $969,198.00 +145.9%N/A0.5 $9.78 12/15/202040,300 shares $257,517.00 +75.2%N/A0.2 $6.39 11/30/202023,000 shares $132,250.00 +10.1%N/A0.2 $5.75 11/15/202020,900 shares $87,362.00 -34.7%N/A0.3 $4.18 10/30/202032,000 shares $132,160.00 +33.3%N/A0.7 $4.13 10/15/202024,000 shares $114,000.00 +8.1%N/A0.4 $4.75 9/30/202022,200 shares $94,128.00 +7.8%N/A0.4 $4.24 9/15/202020,600 shares $88,786.00 -21.1%N/A0.4 $4.31 8/31/202026,100 shares $123,975.00 +12.5%N/A0.4 $4.75 8/14/202023,200 shares $124,120.00 +373.5%N/A0.3 $5.35 7/31/20204,900 shares $29,155.00 -54.2%N/A0.1 $5.95 7/15/202010,700 shares $63,130.00 -15.8%N/A0.1 $5.90 6/30/202012,700 shares $85,344.00 -35.2%N/A0.2 $6.72 6/15/202019,600 shares $91,728.00 -14.0%0.2%0.3 $4.68 5/29/202022,800 shares $105,336.00 -33.9%0.2%0.4 $4.62 5/15/202034,500 shares $155,250.00 +155.6%0.3%0.6 $4.50 4/30/202013,500 shares $54,675.00 +82.4%0.1%0.3 $4.05 4/15/20207,400 shares $23,236.00 +124.2%0.1%0.2 $3.14 3/31/20203,300 shares $12,045.00 -10.8%0.0%0.1 $3.65 3/13/20203,700 shares $10,952.00 -30.2%0.0%0.1 $2.96 2/28/20205,300 shares $12,243.00 -51.4%0.1%0.1 $2.31 2/14/202010,900 shares $44,581.00 +29.8%0.1%0.2 $4.09 1/31/20208,400 shares $42,504.00 -46.5%0.1%0.2 $5.06 DMAC Short Interest - Frequently Asked Questions What is DiaMedica Therapeutics' current short interest? Short interest is the volume of DiaMedica Therapeutics shares that have been sold short but have not yet been closed out or covered. As of December 31st, traders have sold 222,800 shares of DMAC short. Learn More on DiaMedica Therapeutics' current short interest. What is a good short interest ratio for DiaMedica Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DMAC shares currently have a short interest ratio of 2.0. Learn More on DiaMedica Therapeutics's short interest ratio. Is DiaMedica Therapeutics' short interest increasing or decreasing? DiaMedica Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 222,800 shares, an increase of 14.5% from the previous total of 194,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does DiaMedica Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to DiaMedica Therapeutics: ArriVent BioPharma, Inc. (19.54%), Phibro Animal Health Co. (3.79%), Relay Therapeutics, Inc. (8.93%), Cogent Biosciences, Inc. (7.22%), Avid Bioservices, Inc. (17.51%), Sana Biotechnology, Inc. (30.31%), Avadel Pharmaceuticals plc (12.21%), Tyra Biosciences, Inc. (8.27%), Cronos Group Inc. (1.64%), Immatics (8.02%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.83 billion), Charter Communications, Inc. ($3.77 billion), Reddit, Inc. ($2.98 billion), The Kroger Co. ($2.97 billion), International Paper ($2.64 billion), SoFi Technologies, Inc. ($1.99 billion), Rivian Automotive, Inc. ($1.93 billion), Onsemi ($1.81 billion), SoundHound AI, Inc. ($1.59 billion), and Moderna, Inc. ($1.57 billion). View all of the most shorted stocks. What does it mean to sell short DiaMedica Therapeutics stock? Short selling DMAC is an investing strategy that aims to generate trading profit from DiaMedica Therapeutics as its price is falling. DMAC shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against DiaMedica Therapeutics? A short squeeze for DiaMedica Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of DMAC, which in turn drives the price of the stock up even further. How often is DiaMedica Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DMAC, twice per month. The most recent reporting period available is December, 31 2024. More Short Interest Resources from MarketBeat Related Companies ArriVent BioPharma Short Interest Phibro Animal Health Short Interest Relay Therapeutics Short Interest Cogent Biosciences Short Interest Avid Bioservices Short Interest Sana Biotechnology Short Interest Avadel Pharmaceuticals Short Interest Tyra Biosciences Short Interest Cronos Group Short Interest Immatics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:DMAC) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DMAC Stock Alerts